Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 947

1.

Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.

Gabriel CA, Tigges-Cardwell J, Stopfer J, Erlichman J, Nathanson K, Domchek SM.

Fam Cancer. 2009;8(1):23-8. doi: 10.1007/s10689-008-9208-6. Epub 2008 Aug 29.

PMID:
18758995
2.

Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.

Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ.

Am J Surg Pathol. 2009 Aug;33(8):1125-36. doi: 10.1097/PAS.0b013e31819e986a.

PMID:
19440148
3.

Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van 't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL; PROSE Study Group.

J Clin Oncol. 2005 Nov 1;23(31):7804-10. Epub 2005 Oct 11.

PMID:
16219936
4.

Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.

Finch A, Metcalfe K, Lui J, Springate C, Demsky R, Armel S, Rosen B, Murphy J, Elit L, Sun P, Narod S.

Clin Genet. 2009 Mar;75(3):220-4.

PMID:
19263514
5.

Single-port risk-reducing salpingo-oophorectomy with and without hysterectomy: surgical outcomes and learning curve analysis.

Escobar PF, Starks DC, Fader AN, Barber M, Rojas-Espalliat L.

Gynecol Oncol. 2010 Oct;119(1):43-7. doi: 10.1016/j.ygyno.2010.05.026. Epub 2010 Jun 25.

PMID:
20579712
6.

A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer.

Michelsen TM, Dørum A, Dahl AA.

Gynecol Oncol. 2009 Apr;113(1):128-33. doi: 10.1016/j.ygyno.2008.12.024. Epub 2009 Jan 29. Review.

PMID:
19178933
7.

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K.

N Engl J Med. 2002 May 23;346(21):1609-15. Epub 2002 May 20.

8.
9.

Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers.

Domchek SM, Stopfer JE, Rebbeck TR.

J Natl Compr Canc Netw. 2006 Feb;4(2):177-82. Review.

PMID:
16451773
10.

Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.

Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, Komaromy M, Beattie M, Ziegler J.

J Clin Oncol. 2005 Jan 1;23(1):127-32.

PMID:
15625367
11.

Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Lubinski J, Neuhausen SL, Lynch HT, Rosen B, Ainsworth P, Moller P, Ghadirian P, Isaacs C, Karlan B, Sun P, Narod SA.

Gynecol Oncol. 2006 Jan;100(1):83-8. Epub 2005 Aug 31.

PMID:
16137751
12.

Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.

Powell CB, Chen LM, McLennan J, Crawford B, Zaloudek C, Rabban JT, Moore DH, Ziegler J.

Int J Gynecol Cancer. 2011 Jul;21(5):846-51. doi: 10.1097/IGC.0b013e31821bc7e3.

PMID:
21670699
13.

Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.

Gadducci A, Biglia N, Cosio S, Sismondi P, Genazzani AR.

Gynecol Endocrinol. 2010 Aug;26(8):568-77. doi: 10.3109/09513590.2010.487609. Review.

PMID:
20632911
14.

Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.

Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM.

Am J Obstet Gynecol. 2006 Jun;194(6):1702-9.

PMID:
16731090
15.

Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.

Rebbeck TR, Kauff ND, Domchek SM.

J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13.

16.

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.

17.

Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.

Kenkhuis MJ, de Bock GH, Elferink PO, Arts HJ, Oosterwijk JC, Jansen L, Mourits MJ.

Maturitas. 2010 Jul;66(3):310-4. doi: 10.1016/j.maturitas.2010.03.018. Epub 2010 Apr 21.

PMID:
20409655
18.

Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.

Morgan D, Sylvester H, Lucas FL, Miesfeldt S.

Fam Cancer. 2009;8(4):277-87. doi: 10.1007/s10689-009-9242-z. Epub 2009 Apr 4.

PMID:
19347608
19.

Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.

Fakkert IE, Mourits MJ, Jansen L, van der Kolk DM, Meijer K, Oosterwijk JC, van der Vegt B, Greuter MJ, de Bock GH.

Cancer Prev Res (Phila). 2012 Nov;5(11):1291-7. doi: 10.1158/1940-6207.CAPR-12-0190. Epub 2012 Sep 25.

20.

Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.

Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL.

J Natl Cancer Inst. 1999 Sep 1;91(17):1475-9.

PMID:
10469748

Supplemental Content

Support Center